Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective δ agonist (+)-4- [(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]N,N- diethylbenzamide (SNC 80) and related novel nonpeptide δ opioid receptor ligands

Journal of Medicinal Chemistry

Volumn 40, Issue 5, 1997, Pages 695-704

  Calderon, Silvia N ^a   Rice, Kenner C ^a   Rothman, Richard B ^b   Porreca, Frank ^c   Flippen Anderson, Judith L ^d   Kayakiri, Hiroshi ^a,e   Xu, Heng ^b   Becketts, Karen ^b   Smith, Larren E ^a   Bilsky, Edward J ^c   Davis, Peg ^c   Horvath, Robert ^c  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NIDA Addiction Research Center   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d NAVAL RESEARCH LABORATORY   (United States)

^e ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; OPIATE AGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BIOASSAY; CENTRAL NERVOUS SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENANTIOMER; NONHUMAN; OPTICAL RESOLUTION; RAT; RECEPTOR AFFINITY;

ANIMALS; BENZAMIDES; BINDING, COMPETITIVE; BRAIN; CRYSTALLOGRAPHY, X-RAY; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALIN, LEUCINE-2-ALANINE; ENKEPHALINS; GUINEA PIGS; ILEUM; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; MUSCLE CONTRACTION; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STEREOISOMERISM; VAS DEFERENS;

EID: 14444274551     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960319n     Document Type: Article

References (58)

1. 3H] SNC 121, A Novel, High Affinity and Selective Ligand for Delta Opioid Receptor. J. Labeled Comp. Radiopharm. 1996, 38, 847-850.
2. (a) Pert, C.; Snyder, S. Opiate receptor: Demonstration in Nervous Tissue. Science 1973, 179, 1011-1014.
3. (b) Lord, J.; Waterfield, A.; Hughes, J.; Kosterlitz, H. Endogenous Opioid Peptides: Multiple Agonists and Receptors. Nature 1977, 267, 495-499.
4. (c) Herz, A. The Multiplicity of Opioid Receptors and their Functional Significance. In Trends in Medicinal Chemistry: Proceedings of the 9th International Symposium on Medicinal Chemistry, Berlin, 1986; Mutschler, E., Wintrfeldt, E., Eds.; VCH Verlagsgesellschaft: Weinheim, 1987; pp 337-350.
5. (d) Mattia, A.; Vanderah, T.; Mosberg, H. I.; Porreca, F. Lack of Antinociceptive Cross-tolerance between Enkephalin and Deltorphin II in Mice: Evidence for Delta Receptor Subtypes. J. Pharmacol. Exp. Ther. 1991, 258, 583-587.
6. (e) Rothman, R. B.; Bykov, V.; Xue, B. G.; Xu, H.; de Costa, B. R.; Jacobson, A. E.; Rice, K. C.; Kleinman, J. E.; Brady, L. S. Interaction of Opioid Peptides and Other Drugs with Multiple Kappa receptors in Rat and Human Brain. Evidence for Species Differences. Peptides 1992, 13, 977-987.
7. ncx Binding Sites in Mouse Brain: Further Evidence for δ Receptor Heterogeneity. Peptides 1993, 14, 893-907.
8. (a) Goldstein, A.; Naidu, A. Multiple Opioid Receptors: Ligand Selectivity Profiles and Binding Site Signatures. Mol. Pharmacol. 1989, 36, 265-272.
9. (b) Mansour, A.; Fox, C. A.; Akil, H.; Watson, S. J. Opioid-receptor mRNA Expression in the Rat CNS: Anatomical and Functional Implications. Trends Neurosci. 1995, 18, 22-29.
10. (a) Jiang, Q.; Mosberg, H. I.; Porreca, F. Selective Modulation of Morphine Antinociception, but Not Development of Tolerance, by δ Receptor Agonists. Eur. J. Pharmacol. 1990, 186, 137-141.
11. (b) Horan, P.; Tallarida, R. J.; Haaseth, R. C.; Matsunaga, T. O.; Hruby, V. J.; Porreca, F. Antinociceptive Interactions of Opioid Delta Receptor Agonists with Morphine in Mice: Supra- and Sub-Additivity. Life Sci. 1992, 50, 1535-1541.
12. (c) Porreca, F.; Takemori, A. E.; Sultana, M.; Portoghese, P. S.; Bowen, W. D.; Mosberg, H. I. Modulation of Mu-Mediated Antinociception in the Mouse Involves Opioid Delta-2 Receptors. J. Pharmacol. Exp. Ther. 1992, 263, 147-152.
13. (d) Hammond, D. L. Pharmacological Mechanisms of Pain Modulation. An Update on δ Opioid Receptors. In Current and Emerging Issues in Cancer Pain: Research and Practice; Chapman, C. R., Foley, K. M., Eds.; Raven Press, Ltd.: New York, 1993; pp 175-183.
14. (a) Spanagel, R.; Herz, A.; Shippenberg, T. S. The Effects of Opioid Peptides on Dopamine Release in the Nucleus Accumbens: An In Vivo Microdialysis Study. J. Neurochem. 1990, 55, 1734-1739.
15. (b) Spanagel, R.; Herz, A.; Shippenberg, T. S. Opposing Tonically Active Endogenous Opioid Systems Modulate the Mesolimbic Dopaminergic Pathway. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 2046-2050. Manzanares, J.; Durham, R. A.; Lookingland, K. J.; Moore, K. E. δ-Opioid Receptor-Mediated Regulation of Central Dopaminergic Neurons in the Rat. Eur. J. Pharmacol. 1993, 249, 107-112.
16. (b) Spanagel, R.; Herz, A.; Shippenberg, T. S. Opposing Tonically Active Endogenous Opioid Systems Modulate the Mesolimbic Dopaminergic Pathway. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 2046-2050. Manzanares, J.; Durham, R. A.; Lookingland, K. J.; Moore, K. E. δ-Opioid Receptor-Mediated Regulation of Central Dopaminergic Neurons in the Rat. Eur. J. Pharmacol. 1993, 249, 107-112.
17. (a) Cowan, A.; Zhu, X. Z.; Mosberg, H. I.; Omnaas, J. R.; Porreca, F. Direct Dependence Studies in Rats with Agents Selective for Different Types of Opioid Receptors. J. Pharmacol. Exp. Ther. 1988, 246, 950-955.
18. 2]deltorphin I. Eur. J. Pharmacol. 1993, 267, 852-857.
19. (c) Galligan, J. J.; Mosberg, H. I.; Hurst, R.; Hruby, V. J.; Burks, T. F. Cerebral Delta Opioid Receptors Mediate Analgesia but Not the Intestinal Motility Effects of Intracerebroventriculary Administered Opioids. J. Pharmacol. Exp. Ther. 1984, 229, 641-648.
20. Hurd, Y. S.; Herkenham, M. Molecular Alterations in the Neostriatum of Human Cocaine Addicts. Synapse 1993, 13, 357-369.
21. (a) Zubieta, J.-K.; Gorelick, D.; Dannals, R. F.; Ravert, H. T.; Frost, J. J. Increased Mu-Opioid Receptors in Cocaine Abuse: Association with craving. Abstracts of the 34th Annual Meeting of the American College of Neuropsychopharmacology.
22. (b) Unterwald, E. M. Cocaine Interactions with the Endogenous Opioid System. In The Neurobiology of Cocaine: Cellular and Molecular Mechanisms; Hammer, R. P., Jr., Eds.; CRC Press: Boca Raton; FL, 1995; pp 145-162.
23. 5]enkephalin, in the Rat. Eur. J. Pharmacol. 1993, 231, 143-144.
24. Reid, L. D.; Hubbell, C. L.; Glaccum, M. B.; Bilsky, E. J.; Portoghese, P. S.; Porreca, F. Naltrindole, an Opioid Delta Receptor Antagonist, Blocks Cocaine-Induced Facilitation of Responding for Rewarding Brain Stimulation. Life Sci. 1993, 52, PL 67-71.
25. Shippenberg, T. S.; Heidbreder, C. The δ-Opioid Receptor Antagonist Naltrindole Prevents Sensitization to the Conditioned Rewarding Effects of Cocaine. Eur. J. Pharmacol. 1995, 280, 55-61.
26. Lee, P. H. K.; McNutt, R. W.; Chang, K.-J. A Nonpeptidic Delta-Opioid Receptor Agonist, BW 373U86, Suppresses Naloxone-Precipitated Morphine Abstinence. Abstracts of the 1992 College on Problems of Drug Dependence-International Narcotics Research Conference, Abstract 34.
27. (a) Chang, K.-J.; Rigdon, G. C.; Howard, J. L.; McNutt, R. W. A Novel, Potent and Selective Nonpeptidic Delta Opioid Receptor Agonist BW373U86. J. Pharmacol. Exp. Ther. 1993, 267, 852-857.
28. (b) Wild, K. D.; McCormick, J.; Bilsky, E. J.; Vanderah, T.; McNutt, R. W.; Chang, K.-J.; Porreca, F. Antinociceptive Actions of BW373U86 in the Mouse. J. Pharmacol. Exp. Ther. 1993, 267, 858-865.
29. (c) Comer, S. D.; McNutt, R. W.; Chang, K.-J.; de Costa, B. R.; Mosberg, H. I.; Woods, J. H. Discriminative Stimulus Effects of BW373U86: A Nonpeptide Ligand with Selectivity for Delta Opioid Receptors. J. Pharmacol. Exp. Ther. 1993, 267, 866-874.
30. (c) Lee, P. H. K.; McNutt, R. W.; Chang, K.-J. A Nonpeptidic Delta Opioid Receptor Agonist, BW373U86, Attenuates the Development and Expression of Morphine Abstinence Precipitated by Naloxone in the Rat. J. Pharmacol. Exp. Ther. 1993, 267, 883-887.
31. (d) Comer, S. D.; Hoenicke, E. M.; Sable, A. I.; McNutt, R. W.; Chang, K.-J.; de Costa, B. R.; Mosberg, H. I.; Woods, J. H. Convulsive Effects of Systemic Administration of the Delta Opioid Agonist BW373U86 in Mice. J. Pharmacol. Exp. Ther. 1993, 267, 888-893.
32. (e) Dykstra, L. A.; Schoenbaum, G. M.; Yarbrough, J.; McNutt, R.; Chang, K.-J. A Novel Delta Opioid Agonist, BW373U86, in Squirrel Monkeys Responding Under a Schedule of Shock Titration. J. Pharmacol. Exp. Ther. 1993, 267, 875-882.
33. Calderon, S. N.; Rothman, R. B.; Porreca, F.; Flippen-Anderson, J. L.; McNutt, R. W.; Xu, H.; Smith, L. E.; Bilsky, E. J.; Davis, P.; Rice, K. C. Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of (+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): A Highly Selective, Nonpeptide δ Opioid Receptor Agonist. J. Med. Chem. 1994, 37, 2125-2128.
34. Ariens, E. J. Stereochemistry: A Source of Problems in Medicinal Chemistry. Med. Res. Rev. 1986, 6, 451-466.
35. Bilsky, E. J.; Calderon, S. N.; Wang, T.; Bernstein, R. N.; Davis, P.; Hruby, V.; McNutt, R. W.; Rothman, R. B.; Rice, K. C.; Porreca, F. SNC 80, A Selective, Non-Peptidic and Systemically-Active Opioid Delta Agonist. J. Pharmacol. Exp. Ther. 1995, 273, 359-366.
36. Hunger, A.; Kebrle, J.; Rossi, A.; Hoffman, A. Benzimidazol-Derivate und Verwandte Heterocyclen III) Synthese von 1-Aminoalkyl-2-benzyl-nitro-benzimidazolen. Helv. Chim. Acta 1960, 43, 1032-1046.
37. Ikeda, Y.; Nitta, Y.; Yamada, K. Piperazine Compounds. II. Synthesis of 1-Piperazinylbarbituric acid Derivatives and Some of their Pharmacological Activities. Yakagaku Zasshi 1969, 89, 669-676.
38. (a) Chang, K.-J.; Boswell, G. E.; Bubacz, D. G.; Collins, M. A.; Davis, A. O.; McNutt, R. W. Analgesic Diarylmethylpiperazines and Piperidines. International Patent Application WO 9315062, August 5, 1993; Chem. Abstr. 1994, 121, 83367.
39. (b) Bishop, M. J.; McNutt, R. W. An Efficient Synthesis of the Benzhydrylpiperazine Delta Opioid Agonist (+)-BW373U86. Bioorg. Med. Chem. Lett. 1995, 5, 1311-1314.
40. Boger, D. L.; Yohannes, D. Studies on the Total Synthesis of Bouvardin and Deoxybouvardin: Cyclic Hexapeptide Cyclization Studies and Preparation of Key Partial Structures. J. Org. Chem. 1988, 53, 487-499.
41. Hansen, D. W., Jr.; Pilipauskas, D. Chemoselective N-Ethylation of Boc Amino Acids Without Racemization. J. Org. Chem. 1985, 50, 945-950.
42. Kiely, J. S.; Priebe, S. R. An Improved Synthesis of (R)- and (S)-2-Methylpiperazine. Org. Prep. Proced. Int. 1990, 22, 761-764.
43. Nitecki, D. E.; Halpern, B.; Westley, J. W. A Simple Route to Sterically Pure Diketopiperazines. J. Org. Chem. 1968, 33, 864-866.
44. Rothman, R. B.; Xu, H.; Seggel, M.; Jacobson, A. E.; Rice, K. C.; Brine, G. A.; Carroll, F. I. RTI-4614-4: An Analog of (+)-Cis-3-methylfentanyl with a 27,000-fold Binding Selectivity for Mu Versus Delta Binding Sites. Life Sci. 1991, 48; PL111-PL116.
45. Xu, H.; Partilla, J. S.; de Costa, B. R.; Rice, K. C.; Rothman, R. B. Interaction of Opioid Peptides and Other Drugs with Multiple δncx Binding Sites in Rat Brain: Further Evidence for Heterogenity. Peptides 1992, 13, 1207-1213.
46. Cahn, R. S.; Ingold, C.; Prelog, V. Specification of Molecular Chirality. Angew. Chem., Int. Ed. Engl. 1966, 5, 385-415.
47. Calderon, S. N.; Flippen-Anderson, J.; Xu, H.; Becketts, K. M.; Rothman, R. B.; Davis, P.; Porreca, F.; Rice, K. C. Synthesis, Binding and Bioassay Studies of SNC 80 and Related Nonpeptidic Delta Opioid Receptor Agonists. Problems of Drug Dependence, 1995; Harris, L. S., Ed.; NIDA Research Monograph: Washington, DC, 1996, in press.
48. Kramer, T. H.; Davis, P.; Hruby, V. J.; Burks, T. F.; Porreca, F. In Vitro Potency, Affinity and Agonist Efficacy of Highly Selective Delta Opioid Receptor Ligands. J. Pharmacol. Exp. Ther. 1993, 266, 577-584. Proceedings of the College on Problems of Drug Dependence, 1996.
49. Cotton, R.; Gills, M. G.; Miller, L.; Shaw, J. S.; Timms, D. ICI 174,864: A Highly Selective Antagonist for the Opioid δ Receptor. Eur. J. Pharmacol. 1984, 97, 331-332.
50. Kramer, T. H.; Shook, J. E.; Kazmierski, W.; Ayres, E. A.; Wire, W. S.; Hruby, V. J.; Burks, T. F. Novel Peptidic Mu Opioid Antagonists: Pharmacologic Characterization in Vitro and in Vivo. J. Pharmacol. Exp. Ther. 1989, 249, 544-551.
51. (a) Nagase, H.; Wakita, H.; Kawei, K.; Endoh, T.; Matsuura, H.; Tanaka, C.; Takezawa, Y. Synthesis of Non-Peptidic Delta Opioid Agonists and their Structure Activity Relationships. Jpn. J. Pharmacol. 1994, 64, Suppl. I, 35P.
52. (b) Kamei, J.; Saitoh, A.; Oshsawa, M.; Suzuki, T.; Misawa, M.; Nagase, H.; Kasuya, Y. Antinociceptive Effects of the Selective Non-peptidic δ-Opioid Receptor Agonist TAN-67 in Diabetic Mice. Eur. J. Pharmacol. 1995, 276, 131-135.
53. (c) Colle, R.; Vecchietti, V.; Dondio, G.; Ronzoni, S. Preparation of Hydroindoloisoquinoline Derivatives and Analogs as δ-Receptor Agonists. International Patent Application WO 9301186, January 21, 1993; Chem. Abstr. 1993, 119, 8795.
54. Sheldrick, G. M. SHELXTL-Plus, Release 4.2; Siemens Analytical X-ray Instruments, Inc.: Madison, WI, 1992.
55. Sheldrick, G. M.; Schneider, T. R. Methods Enzymol., in press.
56. Atomic coordinates may be obtained from the Cambridge Crystallographic Data Centre (Cambridge University Chemical Laboratory, Cambridge CB2 1EW, U.K.).
57. 3H]D-Ala2-D-Leu5-enkephalin Binding Site. Neuropeptides 1988, 11, 13-16.
58. MINSQ Least Squares Parameter Estimation, Version 3.05; MicroMath, Inc., 1989.